PortalPublikationenvWF, a screening tool for detection of hepatopulmonary syndr...

vWF, a screening tool for detection of hepatopulmonary syndrome in patients with liver cirrhosis

Standard

vWF, a screening tool for detection of hepatopulmonary syndrome in patients with liver cirrhosis. / Horvatits, Thomas; Drolz, Andreas; Roedl, Kevin; Herkner, Harald; Ferlitsch, Arnulf; Perkmann, Thomas; Müller, Christian; Trauner, Michael; Schenk, Peter; Fuhrmann, Valentin.

in: J HEPATOL, Jahrgang 61, Nr. 3, 2014, S. 544-549.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Horvatits, T, Drolz, A, Roedl, K, Herkner, H, Ferlitsch, A, Perkmann, T, Müller, C, Trauner, M, Schenk, P & Fuhrmann, V 2014, 'vWF, a screening tool for detection of hepatopulmonary syndrome in patients with liver cirrhosis', J HEPATOL, Jg. 61, Nr. 3, S. 544-549. https://doi.org/10.1016/j.jhep.2014.04.025

APA

Horvatits, T., Drolz, A., Roedl, K., Herkner, H., Ferlitsch, A., Perkmann, T., Müller, C., Trauner, M., Schenk, P., & Fuhrmann, V. (2014). vWF, a screening tool for detection of hepatopulmonary syndrome in patients with liver cirrhosis. J HEPATOL, 61(3), 544-549. https://doi.org/10.1016/j.jhep.2014.04.025

Vancouver

Horvatits T, Drolz A, Roedl K, Herkner H, Ferlitsch A, Perkmann T et al. vWF, a screening tool for detection of hepatopulmonary syndrome in patients with liver cirrhosis. J HEPATOL. 2014;61(3):544-549. https://doi.org/10.1016/j.jhep.2014.04.025

Bibtex

@article{2ad3fc1ed1b34d738f10e02489f57390,
title = "vWF, a screening tool for detection of hepatopulmonary syndrome in patients with liver cirrhosis",
abstract = "BACKGROUND & AIMS: Hepatopulmonary syndrome (HPS) occurs in 20-30% of patients with liver cirrhosis and is associated with a >2 fold increased mortality. Endothelial dysfunction seems to play a central role in its pathogenesis. von Willebrand factor antigen (vWF-Ag), an established marker of endothelial dysfunction, is significantly elevated in patients with liver cirrhosis, portal hypertension and in experimental HPS. Aim of the present study was to evaluate the impact of vWF-Ag as screening marker for presence of HPS in patients with stable cirrhosis.METHODS: 145 patients with stable liver cirrhosis were screened for presence of HPS in this prospective cohort type cross sectional diagnostic study. vWF-Ag and SaO2 levels were assessed at time of screening for HPS. Criteria of HPS were fulfilled in 31 (21%) patients.RESULTS: vWF-Ag levels were significantly higher in patients with HPS compared to patients without HPS (P < 0.001). Furthermore, vWF-Ag correlated significantly with gas exchange in HPS positive patients (P < 0.05). vWF-Ag is an independent predictor of HPS after correction for sex, age, model for endstage-liver disease (MELD) and hepatic venous pressure gradient (HVPG) (OR per 1% increase of vWF-Ag: 1.02, 95% CI: 1.00-1.04, P < 0.05). The best cut off was 328% at a sensitivity of 100% and specificity of 53.5%; positive predictive value: 36.9%; negative predictive value: 100%.CONCLUSION: HPS is associated with elevated vWF-Ag levels. vWF-Ag may be a useful screening tool for early detection of HPS. Further studies investigating vWF-Ag in HPS will be needed to confirm our findings.",
author = "Thomas Horvatits and Andreas Drolz and Kevin Roedl and Harald Herkner and Arnulf Ferlitsch and Thomas Perkmann and Christian M{\"u}ller and Michael Trauner and Peter Schenk and Valentin Fuhrmann",
note = "Copyright {\textcopyright} 2014. Published by Elsevier B.V.",
year = "2014",
doi = "10.1016/j.jhep.2014.04.025",
language = "English",
volume = "61",
pages = "544--549",
journal = "J HEPATOL",
issn = "0168-8278",
publisher = "Elsevier",
number = "3",

}

RIS

TY - JOUR

T1 - vWF, a screening tool for detection of hepatopulmonary syndrome in patients with liver cirrhosis

AU - Horvatits, Thomas

AU - Drolz, Andreas

AU - Roedl, Kevin

AU - Herkner, Harald

AU - Ferlitsch, Arnulf

AU - Perkmann, Thomas

AU - Müller, Christian

AU - Trauner, Michael

AU - Schenk, Peter

AU - Fuhrmann, Valentin

N1 - Copyright © 2014. Published by Elsevier B.V.

PY - 2014

Y1 - 2014

N2 - BACKGROUND & AIMS: Hepatopulmonary syndrome (HPS) occurs in 20-30% of patients with liver cirrhosis and is associated with a >2 fold increased mortality. Endothelial dysfunction seems to play a central role in its pathogenesis. von Willebrand factor antigen (vWF-Ag), an established marker of endothelial dysfunction, is significantly elevated in patients with liver cirrhosis, portal hypertension and in experimental HPS. Aim of the present study was to evaluate the impact of vWF-Ag as screening marker for presence of HPS in patients with stable cirrhosis.METHODS: 145 patients with stable liver cirrhosis were screened for presence of HPS in this prospective cohort type cross sectional diagnostic study. vWF-Ag and SaO2 levels were assessed at time of screening for HPS. Criteria of HPS were fulfilled in 31 (21%) patients.RESULTS: vWF-Ag levels were significantly higher in patients with HPS compared to patients without HPS (P < 0.001). Furthermore, vWF-Ag correlated significantly with gas exchange in HPS positive patients (P < 0.05). vWF-Ag is an independent predictor of HPS after correction for sex, age, model for endstage-liver disease (MELD) and hepatic venous pressure gradient (HVPG) (OR per 1% increase of vWF-Ag: 1.02, 95% CI: 1.00-1.04, P < 0.05). The best cut off was 328% at a sensitivity of 100% and specificity of 53.5%; positive predictive value: 36.9%; negative predictive value: 100%.CONCLUSION: HPS is associated with elevated vWF-Ag levels. vWF-Ag may be a useful screening tool for early detection of HPS. Further studies investigating vWF-Ag in HPS will be needed to confirm our findings.

AB - BACKGROUND & AIMS: Hepatopulmonary syndrome (HPS) occurs in 20-30% of patients with liver cirrhosis and is associated with a >2 fold increased mortality. Endothelial dysfunction seems to play a central role in its pathogenesis. von Willebrand factor antigen (vWF-Ag), an established marker of endothelial dysfunction, is significantly elevated in patients with liver cirrhosis, portal hypertension and in experimental HPS. Aim of the present study was to evaluate the impact of vWF-Ag as screening marker for presence of HPS in patients with stable cirrhosis.METHODS: 145 patients with stable liver cirrhosis were screened for presence of HPS in this prospective cohort type cross sectional diagnostic study. vWF-Ag and SaO2 levels were assessed at time of screening for HPS. Criteria of HPS were fulfilled in 31 (21%) patients.RESULTS: vWF-Ag levels were significantly higher in patients with HPS compared to patients without HPS (P < 0.001). Furthermore, vWF-Ag correlated significantly with gas exchange in HPS positive patients (P < 0.05). vWF-Ag is an independent predictor of HPS after correction for sex, age, model for endstage-liver disease (MELD) and hepatic venous pressure gradient (HVPG) (OR per 1% increase of vWF-Ag: 1.02, 95% CI: 1.00-1.04, P < 0.05). The best cut off was 328% at a sensitivity of 100% and specificity of 53.5%; positive predictive value: 36.9%; negative predictive value: 100%.CONCLUSION: HPS is associated with elevated vWF-Ag levels. vWF-Ag may be a useful screening tool for early detection of HPS. Further studies investigating vWF-Ag in HPS will be needed to confirm our findings.

U2 - 10.1016/j.jhep.2014.04.025

DO - 10.1016/j.jhep.2014.04.025

M3 - SCORING: Journal article

C2 - 24798623

VL - 61

SP - 544

EP - 549

JO - J HEPATOL

JF - J HEPATOL

SN - 0168-8278

IS - 3

ER -